Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  panobinostat
Find trials that include:  Any drugs shown
Results 1-13 of 13 for your search:
Start Over
Ixazomib, Panobinostat, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CASE 4A13, NCI-2014-00228, NCI-2014-00267, CLBH589DUS92T, US92T, NCT02057640
Everolimus and Panobinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: Pro00012947, NCI-2013-02164, NCT00978432
Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan before Stem Cell Transplant in Treating Patients with Refractory or Relapsed Multiple Myeloma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 65
Trial IDs: 2014-0516, NCI-2015-01308, NCT02506959
Panobinostat, Bortezomib, and Vincristine Sulfate Liposome with Re-induction Therapy in Treating Younger Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: TSALV, NCI-2015-00935, NCT02518750
Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: MCC-18374, NCI-2016-00054, Novartis CLBH589BUS100T, NCT02588339
Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CLBH589D2222, NCI-2016-00234, NCT02654990
Panobinostat Maintenance Therapy in Treating Patients with Multiple Myeloma after Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC-18430, NCI-2016-00910, NCT02722941
Panobinostat in Treating Patients with Recurrent or Refractory Hodgkin or Non-Hodgkin Lymphoma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 147408, NCI-2009-01605, NCT01032148
Panobinostat, Cytarabine, and Daunorubicin Hydrochloride in treating Older Patients With Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
Status: Active
Phase: Phase I
Type: Treatment
Age: 60 and over
Trial IDs: 112512, NCI-2011-03532, NCT01463046
Panobinostat, Lenalidomide, Bortezomib, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 13-262, NCI-2013-02008, CLBH589BUS82T, NCT01965353
Panobinostat and Ipilimumab in Treating Patients With Stage III or IV Melanoma That Cannot Be Removed By Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MCC 17439, NCI-2014-00176, NCT02032810
Panobinostat, Fludarabine Phosphate, and Cytarabine in Treating Younger Patients with Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 24 and under
Trial IDs: PANAML, NCI-2016-00098, NCT02676323
Panobinostat in Treating Younger Patients with Progressive Diffuse Intrinsic Pontine Glioma
Status: Active
Phase: Phase I
Type: Treatment
Age: 2 to 21
Trial IDs: PBTC-047, NCI-2015-01919, NCT02717455
Start Over